Literature DB >> 22133121

DNA methylation testing and marker validation using PCR: diagnostic applications.

Gerda Egger1, Matthias Wielscher, Walter Pulverer, Albert Kriegner, Andreas Weinhäusel.   

Abstract

DNA methylation provides a fundamental epigenetic mechanism to establish and promote cell-specific gene-expression patterns, which are inherited by subsequent cell generations. Thus, the epigenome determines the differentiation into a cell lineage but can also program cells to become abnormal or malignant. In humans, different germline and somatic diseases have been linked to faulty DNA methylation. In this article, we will discuss the available PCR-based technologies to assess differences in DNA methylation levels mainly affecting 5-methylcytosine in the CpG dinucleotide context in hereditary syndromal and somatic pathological conditions. We will discuss some of the current diagnostic applications and provide an outlook on how DNA methylation-based biomarkers might provide novel tools for diagnosis, prognosis or patient stratification for diseases such as cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22133121     DOI: 10.1586/erm.11.90

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  9 in total

1.  Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells.

Authors:  Maria Chimonidou; Galatea Kallergi; Vassilis Georgoulias; Danny R Welch; Evi S Lianidou
Journal:  Mol Cancer Res       Date:  2013-06-06       Impact factor: 5.852

2.  Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD.

Authors:  Matthias Wielscher; Klemens Vierlinger; Ulrike Kegler; Rolf Ziesche; Andrea Gsur; Andreas Weinhäusel
Journal:  EBioMedicine       Date:  2015-07-02       Impact factor: 8.143

3.  A fast-and-robust profiler for improving polymerase chain reaction diagnostics.

Authors:  George J Besseris
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

4.  Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer.

Authors:  Butuo Li; Chao Jiang; Yiyue Xu; Xinyu Fan; Linlin Yang; Bing Zou; Bingjie Fan; Linlin Wang
Journal:  BMC Cancer       Date:  2022-07-29       Impact factor: 4.638

Review 5.  Epigenomics of cancer - emerging new concepts.

Authors:  Melanie R Hassler; Gerda Egger
Journal:  Biochimie       Date:  2012-05-17       Impact factor: 4.079

6.  A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype.

Authors:  Ryan W Serra; Minggang Fang; Sung Mi Park; Lloyd Hutchinson; Michael R Green
Journal:  Elife       Date:  2014-03-12       Impact factor: 8.140

7.  MSRE-HTPrimer: a high-throughput and genome-wide primer design pipeline optimized for epigenetic research.

Authors:  Ram Vinay Pandey; Walter Pulverer; Pulverer Walter; Rainer Kallmeyer; Gabriel Beikircher; Stephan Pabinger; Albert Kriegner; Andreas Weinhäusel
Journal:  Clin Epigenetics       Date:  2016-03-05       Impact factor: 6.551

8.  DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.

Authors:  Simon Peter Gampenrieder; Gabriel Rinnerthaler; Hubert Hackl; Walter Pulverer; Andreas Weinhaeusel; Suzana Ilic; Clemens Hufnagl; Cornelia Hauser-Kronberger; Alexander Egle; Angela Risch; Richard Greil
Journal:  Theranostics       Date:  2018-03-11       Impact factor: 11.556

9.  DNA Methylation Is Correlated with Gene Expression during Diapause Termination of Early Embryonic Development in the Silkworm (Bombyx mori).

Authors:  Bing Li; Pei Hu; Lin-Bao Zhu; Ling-Ling You; Hui-Hua Cao; Jie Wang; Shang-Zhi Zhang; Ming-Hui Liu; Shahzad Toufeeq; Shou-Jun Huang; Jia-Ping Xu
Journal:  Int J Mol Sci       Date:  2020-01-20       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.